Medicine guide

Kinzalmono (previously Telmisartan Boehringer Ingelheim Pharma KG)

Prescription status not stated
Heart, blood pressure and circulation

Active substance: Telmisartan
Used in: Heart, blood pressure and circulation
Made by: Bayer AG
Source: Official label

Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.

What it is for

Kinzalmono belongs to a class of medicines known as angiotensin II receptor blockers. Angiotensin II is a substance produced in your body which causes your blood vessels to narrow, thus increasing your blood pressure. Kinzalmono blocks the effect of angiotensin II so that the blood vessels relax, and your blood pressure is lowered.
Kinzalmono is used to treat essential hypertension (high blood pressure) in adults. ‘Essential’ means that the high blood pressure is not caused by any other condition.
High blood pressure, if not treated, can damage blood vessels in several organs, which could lead sometimes to heart attack, heart or kidney failure, stroke, or blindness. There are usually no symptoms of high blood pressure before damage occurs. Thus it is important to regularly measure blood pressure to verify if it is within the normal range.
Kinzalmono is also used to reduce cardiovascular events (i.e. heart attack or stroke) in adults who are at risk because they have a reduced or blocked blood supply to the heart or legs, or have had a stroke or have high risk diabetes. Your doctor can tell you if you are at high risk for such events.

From the package leaflet in EMA’s product information, p. 33 · 2025-04-23

Do not take it if

if you are allergic to telmisartan or any of the other ingredients of this medicine (listed in section 6).
if you are more than 3 months pregnant. (It is also better to avoid Kinzalmono in early pregnancy – see pregnancy section.)
if you have severe liver problems such as cholestasis or biliary obstruction (problems with drainage of the bile from the liver and gall bladder) or any other severe liver disease.
if you have diabetes or impaired kidney function and you are treated with a blood pressure lowering medicine containing aliskiren.
If any of the above applies to you, tell your doctor or pharmacist before taking Kinzalmono.

From the package leaflet in EMA’s product information, p. 33.

How to take it

These directions are for this exact strength and form. Another one is different.

Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.
The recommended dose is one tablet a day. Try to take the tablet at the same time each day.
You can take Kinzalmono with or without food. The tablets should be swallowed whole with some water or other non-alcoholic drink. It is important that you take Kinzalmono every day until your doctor tells you otherwise. If you have the impression that the effect of Kinzalmono is too strong or too weak, talk to your doctor or pharmacist.
For treatment of high blood pressure, the usual dose of Kinzalmono for most patients is one 40 mg tablet once a day to control blood pressure over the 24-hour period. Your doctor has recommended a lower dose of one 20 mg tablet daily. Kinzalmono may also be used in combination with diuretics (‘water tablets’) such as hydrochlorothiazide which has been shown to have an additive blood pressure lowering effect with Kinzalmono.
For reduction of cardiovascular events, the usual dose of Kinzalmono is one 80 mg tablet once a day.
At the beginning of the preventive therapy with Kinzalmono 80 mg, blood pressure should be frequently monitored.
If your liver is not working properly, the usual dose should not exceed 40 mg once daily.
If you take more Kinzalmono than you should If you accidentally take too many tablets, contact your doctor, pharmacist, or your nearest hospital emergency department immediately.
If you forget to take Kinzalmono If you forget to take a dose, do not worry. Take it as soon as you remember then carry on as before. If you do not take your tablet on one day, take your normal dose on the next day. Do not take a double dose to make up for forgotten individual doses.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

From the package leaflet in EMA’s product information, p. 35–36.

Warnings and precautions

Talk to your doctor before taking Kinzalmono if you are suffering or have ever suffered from any of the following conditions or illnesses:
Kidney disease or kidney transplant.
Renal artery stenosis (narrowing of the blood vessels to one or both kidneys).
Liver disease.
Heart trouble.
Raised aldosterone levels (water and salt retention in the body along with imbalance of various blood minerals).
Low blood pressure (hypotension), likely to occur if you are dehydrated (excessive loss of body water) or have salt deficiency due to e.g. diuretic therapy (‘water tablets’), low-salt diet, diarrhoea, or vomiting.
Elevated potassium levels in your blood.
Diabetes.
Talk to your doctor before taking Kinzalmono:
if you are taking any of the following medicines used to treat high blood pressure:
an ACE-inhibitor (for example enalapril, lisinopril, ramipril), in particular if you have diabetes-related kidney problems.
aliskiren.
Your doctor may check your kidney function, blood pressure, and the amount of electrolytes (e.g. potassium) in your blood at regular intervals. See also information under the heading “Do not take Kinzalmono”.
if you are taking digoxin.
Talk to your doctor if you experience abdominal pain, nausea, vomiting or diarrhoea after taking Kinzalmono. Your doctor will decide on further treatment. Do not stop taking Kinzalmono on your own.
You must tell your doctor if you think you are (or might become) pregnant. Kinzalmono is not recommended in early pregnancy, and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if used at that stage (see pregnancy section).
In case of surgery or anaesthesia, you should tell your doctor that you are taking Kinzalmono.
Kinzalmono may be less effective in lowering the blood pressure in black patients.
Children and adolescents The use of Kinzalmono in children and adolescents up to the age of 18 years is not recommended.

From the package leaflet in EMA’s product information, p. 34.

Pregnancy and breastfeeding

You must tell your doctor if you think you are (or might become) pregnant. Your doctor will normally advise you to stop taking Kinzalmono before you become pregnant or as soon as you know you are pregnant and will advise you to take another medicine instead of Kinzalmono. Kinzalmono is not recommended in early pregnancy, and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if used after the third month of pregnancy.
Breast-feeding Tell your doctor if you are breast-feeding or about to start breast-feeding. Kinzalmono is not recommended for mothers who are breast-feeding, and your doctor may choose another treatment for you if you wish to breast-feed, especially if your baby is newborn, or was born prematurely.

From the package leaflet in EMA’s product information, p. 35.

Other medicines

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. Your doctor may need to change the dose of these other medications or take other precautions. In some cases you may have to stop taking one of the medicines. This applies especially to the medicines listed below taken at the same time with Kinzalmono:
Lithium containing medicines to treat some types of depression.
Medicines that may increase blood potassium levels such as salt substitutes containing potassium, potassium-sparing diuretics (certain ‘water tablets’), ACE inhibitors, angiotensin II receptor blockers, NSAIDs (non steroidal anti-inflammatory medicines, e.g. aspirin or ibuprofen), heparin, immunosuppressives (e.g. cyclosporin or tacrolimus), and the antibiotic trimethoprim.
Diuretics (‘water tablets’), especially if taken in high doses together with Kinzalmono, may lead to excessive loss of body water and low blood pressure (hypotension).
If you are taking an ACE-inhibitor or aliskiren (see also information under the headings “Do not take Kinzalmono” and “Warnings and precautions”).
Digoxin.
The effect of Kinzalmono may be reduced when you take NSAIDs (non steroidal anti-inflammatory medicines, e.g. aspirin or ibuprofen) or corticosteroids.
Kinzalmono may increase the blood pressure lowering effect of other medicines used to treat high blood pressure or of medicines with blood pressure lowering potential (e.g. baclofen, amifostine).
Furthermore, low blood pressure may be aggravated by alcohol, barbiturates, narcotics or antidepressants. You may notice this as dizziness when standing up. You should consult with your doctor if you need to adjust the dose of your other medicine while taking Kinzalmono.

From the package leaflet in EMA’s product information, p. 34–35.

Driving and using machines

Some people may experience side effects such as fainting or a feeling of spinning (vertigo) when taking Kinzalmono. If you experience these side effects, do not drive or operate machinery.
Kinzalmono contains sorbitol.
This medicine contains 84.32 mg sorbitol in each tablet.
Kinzalmono contains sodium This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially ‘sodium- free’.

From the package leaflet in EMA’s product information, p. 35.

Side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.
Some side effects can be serious and need immediate medical attention You should see your doctor immediately if you experience any of the following symptoms:
Sepsis* (often called “blood poisoning”, is a severe infection with whole-body inflammatory response), rapid swelling of the skin and mucosa (angioedema); these side effects are rare (may affect up to 1 in 1 000 people) but are extremely serious and patients should stop taking the medicine and see their doctor immediately. If these effects are not treated they could be fatal.
Possible side effects of Kinzalmono Common side effects (may affect up to 1 in 10 people):
Low blood pressure (hypotension) in users treated for reduction of cardiovascular events.
Uncommon side effects (may affect up to 1 in 100 people):
Urinary tract infections, upper respiratory tract infections (e.g. sore throat, inflamed sinuses, common cold), deficiency in red blood cells (anaemia), high potassium levels, difficulty falling asleep, feeling sad (depression), fainting (syncope), feeling of spinning (vertigo), slow heart rate (bradycardia), low blood pressure (hypotension) in users treated for high blood pressure, dizziness on standing up (orthostatic hypotension), shortness of breath, cough, abdominal pain, diarrhoea, pain in the belly, bloating, vomiting, itching, increased sweating, drug rash, back pain, muscle cramps, muscle pain (myalgia), kidney impairment (including acute kidney failure), pain in the chest, feeling of weakness, and increased level of creatinine in the blood.
Rare side effects (may affect up to 1 in 1 000 people):
Sepsis* (often called “blood poisoning”, is a severe infection with whole-body inflammatory response which can lead to death), increase in certain white blood cells (eosinophilia), low platelet count (thrombocytopenia), severe allergic reaction (anaphylactic reaction), allergic reaction (e.g. rash, itching, difficulty breathing, wheezing, swelling of the face or low blood pressure), low blood sugar levels (in diabetic patients), feeling anxious, somnolence, impaired vision, fast heart beat (tachycardia), dry mouth, discomfort in the belly, taste disturbance (dysgeusia), abnormal liver function (Japanese patients are more likely to experience this side effect), rapid swelling of the skin and mucosa which can also lead to death (angioedema including fatal outcome), eczema (a skin disorder), redness of skin, hives (urticaria), severe drug rash, joint pain (arthralgia), pain in extremity, tendon pain, flu-like-illness, decreased haemoglobin (a blood protein), increased levels of uric acid, increased hepatic enzymes or creatine phosphokinase in the blood, low levels of sodium.
Very rare side effects (may affect up to 1 in 10 000 people):
Progressive scarring of lung tissue (interstitial lung disease)**.
Not known (frequency cannot be estimated from the available data):
Intestinal angioedema: a swelling in the gut presenting with symptoms like abdominal pain, nausea, vomiting, and diarrhoea has been reported after the use of similar products.
* The event may have happened by chance or could be related to a mechanism currently not known.
** Cases of progressive scarring of lung tissue have been reported during intake of telmisartan.
However, it is not known whether telmisartan was the cause.
Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.

From the package leaflet in EMA’s product information, p. 36–37.

How to store it

Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton after “EXP”. The expiry date refers to the last day of that month.
This medicine does not require any special temperature storage conditions. Store in the original package in order to protect from moisture. Remove your Kinzalmono tablet from the blister only directly prior to intake.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

From the package leaflet in EMA’s product information, p. 37.

Other ingredients

Relevant if you react to a dye, a preservative, lactose or gluten.

The other ingredients are povidone (K25), meglumine, sodium hydroxide, sorbitol (E420) and magnesium stearate.
What Kinzalmono looks like and contents of the pack Kinzalmono 20 mg tablets are white, round and engraved with the code number ‘50H’ on one side and the company logo on the other side.

From the package leaflet in EMA’s product information, p. 37.

Same active substance, strength and form in other countries

Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.

Medicine passport: one printable page to show a pharmacist abroad

United StatesNo exact match for this strength and form

Every strength and form (71)

BulgariaNo exact match for this strength and form

Every strength and form (8)

SpainNo exact match for this strength and form

Every strength and form (91)

FranceNo exact match for this strength and form

Every strength and form (23)

CanadaNo exact match for this strength and form

Every strength and form (36)

NetherlandsNo exact match for this strength and form

Every strength and form (45)

SwitzerlandNo exact match for this strength and form

Every strength and form (10)

Details

Made by	Bayer AG
Active substance	Telmisartan
Used in	Heart, blood pressure and circulation
Classification	C09CA07 · Heart, blood pressure and circulation
Authorised on	1998-12-16
Last updated by the regulator	2025-04-23
EMA product number	EMEA/H/C/000211

Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician

Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).

Report wrong or outdated information on this page

Same active substance

These contain the same substance. That does not mean one can replace another — ask a pharmacist.

ToluraEU authorisation Krka, d.d., Novo mesto · Telmisartan · C09CA07 Telmisartan ActavisEU authorisation Actavis Group PTC ehf · Telmisartan · C09CA07 MicardisEU authorisation Boehringer Ingelheim International GmbH · Telmisartan · C09CA07 PritorEU authorisation Bayer AG · Telmisartan · C09CA07 Telmisartan Teva PharmaEU authorisation Teva B.V. · Telmisartan · C09CA07 Telmisartan TevaEU authorisation Teva B.V. · Telmisartan · C09CA07

See every product with Telmisartan